Effect of novel autologous immune training platform on end-stage patients with cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.2546
Abstract: 2546 Background: SUPLEXA therapeutic cells are the initial autologous and non-engineered candidate to emerge from the novel ENLIST cells training platform. Manufacturing is robust, reproducible and with an acceptable cost of goods. The method requires… read more here.
Keywords: end stage; suplexa therapeutic; stage patients; tumor ... See more keywords